Roivant Sciences SEC Filings

Roivant Sciences Ltd. (ROIV) director Dan Gold reported several open‑market sales of the company’s Common Shares on 11/19/2025. Indirectly through QVT Financial Investment Cayman Ltd., he sold 850,000 shares at $20.25, 150,000 shares at $20.20, 125,000 shares at $20.16, and 175,000 shares at $20.24, all coded as sales. Following these transactions, 18,047,727 Common Shares were beneficially owned indirectly, reported as held by QVT Financial Investment Cayman Ltd. The filing notes that Gold is one of three directors of QVT Financial Investment Cayman Ltd., shares voting and investment control over these shares, and disclaims beneficial ownership beyond his pecuniary interest.

Roivant Sciences Ltd. (ROIV) filed a Form 4 showing a significant shareholder-related sale of common shares. On 11/19/2025, an entity associated with QVT sold a total of 1,300,000 Roivant common shares in four open-market transactions at prices between $20.16 and $20.25 per share. After these sales, 18,047,727 common shares were reported as beneficially owned indirectly through QVT Financial Investment Cayman Ltd.

The explanation notes that QVT Financial LP and its related entities may be deemed to beneficially own 28,081,635 Roivant common shares in aggregate through several affiliated vehicles. QVT states that it disclaims beneficial ownership of these shares except to the extent of any pecuniary interest.

Roivant Sciences Ltd. director and more-than-10% owner Vivek Ramaswamy reported multiple open-market sales of the company’s common shares. On 11/13/2025 he sold 287,283 shares at a weighted average price of $20.81, on 11/14/2025 he sold 1,027,670 shares at a weighted average of $20.33, and on 11/17/2025 he sold 539,650 shares at a weighted average of $20.51. The prices reflect multiple individual trades within stated ranges for each day. After these transactions, he beneficially owned 33,653,756 common shares directly and 13,357,857 common shares indirectly through his spouse.

Roivant Sciences (ROIV) reported Q2 FY2025 results with liquidity remaining strong and continued investment in its pipeline. Cash, cash equivalents and marketable securities were $4,385,835,000 as of September 30, 2025. Revenue was modest at $1,571,000 for the quarter.

Operating expenses were $307,804,000, including research and development of $164,568,000 and general and administrative of $143,125,000. The company recorded a change in fair value of investments of $(128,501,000) and interest income of $(45,341,000), resulting in a net loss attributable to Roivant of $(113,519,000) for the quarter. For the six months, the net loss attributable to Roivant was $(336,874,000).

The board authorized a new common share repurchase program of up to $500,000,000 on June 24, 2025, with no purchases under this program as of September 30, 2025. A prior $1,500,000,000 program was completed in June 2025, including a repurchase of 71,251,083 shares from Sumitomo for approximately $648,400,000. An at-the-market facility has $400,000,000 of capacity remaining. Common shares outstanding were 689,697,370 as of September 30, 2025, and 695,491,615 as of November 3, 2025.

Roivant Sciences (ROIV) furnished quarterly results via an 8‑K. The company reported that it issued a press release announcing financial results for the fiscal quarter ended September 30, 2025, which is attached as Exhibit 99.1. The disclosure under Item 2.02 is provided as “furnished,” not “filed,” and will only be incorporated into other filings if expressly referenced.

Roivant Sciences (ROIV): Officer Eric Venker reported an option exercise and same‑day sale. On 11/07/2025, he exercised 200,000 stock options at an exercise price of $3.85 per share (code M) and sold 200,000 common shares at a weighted average price of $20.22 (code S). Following these transactions, he reported 1,504,959 common shares beneficially owned directly and 6,076,523 derivative securities beneficially owned. The sales were made under a Rule 10b5‑1 trading plan adopted on March 28, 2025.

Venker is listed as President & Immunovant CEO. The options relate to an award with a vesting schedule beginning April 20, 2022, with 25% vesting on the first anniversary and the remainder in 36 equal monthly installments, subject to continuous service.

Roivant Sciences (ROIV) director reported equity award. On 10/20/2025, a director acquired 1,056 Common Shares at $0, received as a fully vested grant under the Non-Employee Director Compensation Plan. After the award, the director beneficially owns 56,904 shares, held directly.

Roivant Sciences (ROIV) director James C. Momtazee reported routine equity activity on 10/20/2025. He received 789 Common Shares as a fully vested award under the company’s Non‑Employee Director Compensation Plan, recorded at $0 per share.

The company also executed a net settlement to cover taxes, withholding 158 shares at a price of $17.74. Following these transactions, Momtazee directly holds 108,543 Common Shares.

Roivant Sciences Ltd. (ROIV) reported insider activity by a director. On 10/20/2025, the director received 1,507 common shares under the Non-Employee Director Compensation Plan, which were fully vested on the grant date.

To cover tax withholding, the issuer executed a net settlement, withholding 281 shares at $17.74. After these transactions, the director directly owns 118,388 shares.